[Application of monoclonal antibody to detect the red cell associated antigen LewisX and sialylated LewisX in the serum of cancer patient].
New monoclonal antibodies, CGAD2 and CSLEX1 detected their red cell associated antigens LewisX and sialylated LewisX in serum of cancer patients by reverse passive hemagglutination. With CGAD2, high titers were noted in 56% of the 27 sera from lung adenocarcinoma patients. Of the total 105 sera from cancer patients, 39% showed a positive reaction. With CSLEX1, 48% of the 85 sera from lung adenocarcinoma and 26% of the 384 sera from various cancer patients showed a positive reaction. None of the sera from 80 healthy subjects reacted with this antibody. By testing with these two monoclonal antibodies, 70% of the 46 sera from lung cancer patients showed a positive reaction. Theoretically, LewisX and sialylated LewisX which are type 2 products of the red cell antigen might be more applicable as a tumor marker than type 1 products such as sialylated Lewisa (CA19-9). Furthermore, LewisX could be a tumor marker in some cases whose levels of CEA were comparatively low. These CGAD2 and CSLEX1 monoclonal antibodies should be potentially useful reagents.